Lexeo Therapeutics, Inc.
Lexeo Therapeutics Inc. is a clinical-stage genetic medicine company focused on developing gene therapy treatments for cardiovascular and neurodegenerative diseases. The company's website is www.lexeotx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lexeo Therapeutics, Inc. does
In the company’s own words
Lexeo Therapeutics Inc. is a clinical-stage genetic medicine company focused on developing gene therapy treatments for cardiovascular and neurodegenerative diseases. The company's website is www.lexeotx.com.
Lexeo's core business centers on advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of serious conditions including Friedreich ataxia cardiomyopathy, arrhythmogenic cardiomyopathy caused by PKP2 mutations, hypertrophic cardiomyopathy, and APOE4-associated Alzheimer's disease. The company's most advanced program, LX2006, is an AAVrh10-based gene therapy currently in Phase 1/2 clinical trials for treating Friedreich ataxia cardiomyopathy, which affects approximately 5,000 patients in the United States. LX2006 has received multiple regulatory designations including Breakthrough Therapy, Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy designations from the FDA.
The company's second most advanced candidate, LX2020, is being evaluated in Phase 1/2 trials for treating PKP2-associated arrhythmogenic cardiomyopathy, which is estimated to affect approximately 60,000 patients in the United States. Additional pipeline programs include LX2021 for Desmoplakin cardiomyopathy, LX2022 for TNNI3-related hypertrophic cardiomyopathy, and programs targeting Alzheimer's disease including LX1001, which has completed Phase 1/2 trials.
Lexeo's technology platform utilizes the AAVrh10 vector, selected for its high transduction efficiency in myocardial cells, favorable cardiac-to-liver biodistribution ratio, and lower pre-existing immunity compared to other AAV serotypes. The company employs a proprietary Sf9 baculovirus manufacturing process designed to produce gene therapy vectors at scale while maintaining quality and cost-effectiveness suitable for larger patient populations.
The company retains exclusive worldwide development and commercialization rights to all its product candidates and maintains intellectual property including in-licensed patents and pending patent applications covering its technology platform and specific therapeutic applications.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1907108
- SIC
- 2836
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lexeo Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lexeo Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lexeo Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lexeo Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lexeo Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”